Risk Factors for Type 1 Diabetes: A Snapshot for Primary Care

Commentary
Slideshow

About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.

Routine screening for type 1 diabetes in the general population is not currently recommended due to its relatively low prevalence. However, screening is strongly advised for high-risk populations—those with a family history of T1D or certain genetic markers associated with increased risk.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity / image credit ©molekuule.be/stock.adobe.com

Ascletis Enters Small Molecule Oral GLP-1 RA Category with Positive Phase 1a Findings in Obesity

Grace Halsey
January 21st 2025
Article

The properties of ASC30 may allow the small molecule GLP-1 RA to be formulated as a monthly injection and daily oral tablet, Ascletis said.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial / image credit ©Starmarpro/stock.adobe.com

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

Grace Halsey
January 17th 2025
Article

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces / image credit courtesy of Mayo Clinic

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

Grace Halsey
January 16th 2025
Article

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management / image credit ©brovarky/stock.adobe.com

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management

Grace Halsey
January 15th 2025
Article

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

© 2025 MJH Life Sciences

All rights reserved.